Results Release and Webinar Discussion on Morning of December 18, 2025MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“Q4 2025”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that d ...

For Repurchase of up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,346 Common Shares ("Shares"), that num ...

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]

Core Insights - Microbix Biosystems Inc. will present to investors at the Muskoka Capital Event from September 26 to 28, 2025, focusing on growth-oriented investors [1][2] - The company aims to engage in 18 one-on-one meetings with investors during the event [2] - Microbix generates revenues targeting C$ 2.0 million or more per month and employs over 120 skilled employees [3] Company Overview - Microbix specializes in proprietary biological products for human health, particularly in the global diagnostics industry [3] - The company produces critical ingredients such as antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are sold in over 30 countries, supported by a network of international distributors [3] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [3] Product Development - Microbix develops proprietary products including Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [4] - The company’s QAPs and QUANTDx products support clinical lab accreditation and diagnostic workflows [3][4] Event Information - The Muskoka Capital Event is organized by Capital Event Management Ltd., featuring public and private companies and a range of investors [5] - The event aims to foster relationships that lead to financings and increased awareness within the investment community [5]

Core Insights - Microbix Biosystems Inc. and EMQN CIC have launched a program to enhance the identification of patients with gene variants affecting the metabolism of Clopidogrel, a widely prescribed antiplatelet drug [1][2] Group 1: EQA Program Details - The new External Quality Assessment (EQA) program aims to ensure proficiency in Point-of-Care Tests (POCTs) that identify three gene variants of the Cytochrome P450 CYP2C19 enzyme, which are critical for determining appropriate Clopidogrel dosing [2][4] - Over 20% of individuals carry these gene variants, which can lead to either overdosing or underdosing of Clopidogrel, posing significant health risks [2][3] Group 2: Market Context - Clopidogrel is prescribed to over 15 million patients annually in the U.S. alone, indicating a substantial market for pharmacogenomic testing to optimize treatment and minimize risks associated with improper dosing [3] - The EQA program will provide participants with three samples every two months, totaling 18 samples per year, to ensure ongoing accuracy in genetic testing [4] Group 3: Company Contributions - Microbix is supplying quality assessment products (QAPs™) for the EQA program, which will assist in evaluating the accuracy of genetic tests and support safe prescription practices [4][5] - The collaboration with EMQN and Copan aims to enhance the quality of genetic testing, with Microbix expanding its role in the field of pharmacogenomics alongside its established presence in infectious diseases and oncology [5][7] Group 4: Company Background - Microbix Biosystems Inc. is a life sciences innovator with over 120 employees, generating revenues of approximately C$2.0 million or more per month, and is involved in manufacturing critical ingredients for the global diagnostics industry [7][8] - The company is ISO 9001 & 13485 accredited and has a presence in over 30 countries, supported by a network of international distributors [8]

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a novel external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying HPV-associated head and neck cancers [1][4] - The EQA program is introduced at the 2025 European Society for Clinical Virology meeting and addresses the need for proficiency checks in laboratories performing HPV-related diagnostics [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing approximately 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program utilizes Microbix's QAPs™ mimetics of HNC patient samples, which include both immunohistochemical (IHC) and PCR targets, to assess laboratory competency [3][5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, targeting revenues of C$ 2.0 million or more per month, and is involved in the global diagnostics industry [7] - Labquality Oy provides external quality assessment services to over 8,000 customers in more than 60 countries, focusing on enhancing laboratory proficiency and patient care [9]

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a new external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying head and neck cancers associated with HPV [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing about 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program was developed to address the lack of proficiency checks for clinical labs working with FFPE samples, which are used for diagnosing HNCs [3] - Microbix created QAPs™ that mimic HNC patient samples, containing both IHC and PCR targets, to support the EQA program [5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating biological products for human health, with revenues targeting C$ 2.0 million or more per month and a focus on the global diagnostics industry [7] - Labquality Oy provides EQA services to over 8,000 customers in more than 60 countries, emphasizing quality in clinical laboratories and point-of-care testing [9]

Core Insights - Microbix Biosystems Inc. hosted Ontario's Minister of Public and Business Service Delivery and Procurement, Stephen Crawford, to showcase its biotechnology facilities and discuss advancements in diagnostics that can enhance health outcomes and reduce healthcare costs for Ontarians [1][2] - The company has received over C$ 2.0 million in grant funding from the Ontario Together Funds, which has supported the development of state-of-the-art manufacturing capabilities and healthcare products [1][3] - Microbix supplied over 2 million units of Viral Transport Medium (VTM) to Ontario during the pandemic years of 2021 and 2022, including a significant emergency order of 1.2 million units in December 2021 [1] Company Overview - Microbix is an Ontario-based life sciences innovator with over 120 skilled employees, producing proprietary biological products for human health [3][4] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are distributed in over 30 countries and are supported by a network of international distributors, with various accreditations including ISO 9001 & 13485 and U.S. FDA registration [3][4] Product Development - Microbix develops proprietary products such as Kinlytic urokinase, a thrombolytic drug for treating blood clots, and reagents for molecular diagnostic testing [4] - The company emphasizes its commitment to innovation and the development of Ontario-made products that contribute to global health [2][3]

Core Insights - Microbix Biosystems Inc. reported disappointing financial results for Q3 and YTD 2025, with significant declines in revenue and net loss compared to the previous year [1][2][6] Financial Performance - Q3 revenue was $3.5 million, a 31% decrease from $5.1 million in Q3 2024, driven by a 44% drop in antigen sales and a 9% decline in QAPs sales [3][11] - Year-to-date (YTD) revenue was $14.8 million, down 22% from $19.1 million in YTD 2024, with antigen revenues up 11% but QAPs revenues down 25% [7][11] - Gross margin for Q3 was 41%, down from 54% in the previous year, primarily due to a less favorable product mix [4][11] - YTD gross margin was 56%, down from 63% in YTD 2024, affected by lower sales of higher-margin products [8][11] Operating Expenses - Operating expenses in Q3 increased by 22% compared to Q3 2024, influenced by lower investment income and the absence of grant income [5][11] - YTD operating expenses rose slightly due to increased investment in R&D and sales and marketing activities [8][11] Net Loss and Cash Flow - The company reported a net loss of $1.6 million for Q3, compared to a net income of $246,746 in Q3 2024 [6][11] - YTD net loss was $765,150, a significant decline from a net income of $3.1 million in YTD 2024 [9][11] - Cash used in operating activities was $1.9 million for Q3, compared to cash provided of $604,064 in Q3 2024 [6][11] Financial Position - As of June 30, 2025, the company had strong cash and equivalents of $12.1 million, with a current ratio of 9.73 and a debt to equity ratio of 0.30, both improved from the previous year [10][11] Corporate Outlook - Management remains cautious about the outlook for the remainder of fiscal 2025, particularly due to reduced sales into China [2][12] - The company aims to drive sales growth across all business lines while improving gross margins and bottom-line results [12]

Core Insights - Microbix Biosystems Inc. is participating in the 2nd Asia Pacific Conference on Point of Care Testing for Infectious Diseases in Bangkok, showcasing its quality assessment products (QAPs) for point-of-care testing [1][2] Group 1: Conference Participation and Presentation - The conference aims to enhance access to rapid diagnostic tools for infectious diseases and features innovations in point-of-care testing [2] - Microbix will present a poster titled "Addressing QC Challenges in Point-of-Care Infectious Disease Testing," highlighting the use of nearly 60,000 QAPs supporting SARS-CoV-2 tests over three years [3] Group 2: Product and Market Impact - Microbix's QAPs have demonstrated reliable quality management system support across diverse usage settings, contributing to its selection as a key quality control device for the EPICC partnership aimed at HPV elimination in the Indo-Pacific [3] - The company is targeting revenues of C$ 2.0 million or more per month and has a presence in over 30 countries through international distributors [5] Group 3: Future Business Development - Discussions with diagnostics program managers and manufacturers are scheduled at the conference to expand Microbix's role in more point-of-care testing programs [4] - Microbix's QAPs are essential for clinical lab proficiency testing and are sold to various stakeholders in the diagnostics industry [5]